Jupiter Neurosciences Strengthens Nugevia Advisory Board with Pharmacy and Wellness Experts
Event summary
- Jupiter Neurosciences appointed Kristopher Fishman and Sanjiv Lal to its Nugevia Advisory Board on April 7, 2026.
- Fishman is CEO of Wells Pharmacy Network, a nationwide compounding pharmacy with operations in 48 states.
- Lal is a healthcare entrepreneur and co-founder of Motivant and RegenTherapy, with expertise in biotechnology and healthcare commercialization.
- Nugevia targets a $1.5 billion addressable market in U.S. practitioner-grade nutraceuticals.
The big picture
Jupiter Neurosciences is strategically positioning Nugevia to capitalize on the growing demand for science-backed longevity products in specialized healthcare channels. The appointments of Fishman and Lal underscore the company's focus on leveraging practitioner trust and formulation quality to differentiate Nugevia in a competitive nutraceutical market. This move aligns with broader industry trends toward clinical-grade supplements and personalized wellness solutions.
What we're watching
- Channel Expansion
- Whether Jupiter can effectively penetrate the compounding pharmacy and wellness channels with Nugevia's clinical-grade formulations.
- Market Differentiation
- How JOTROL's published bioavailability data will position Nugevia against competitors in the practitioner-led nutraceutical space.
- Revenue Growth
- The pace at which Jupiter can scale Nugevia's sales in the $1.5 billion addressable market.
Related topics